Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial

Mazyar Shadman, Paolo F. Caimi, Susan M. O'Brien, Patrick M. Reagan, Bruce Dezube, Punya Navaratnarajah, Tripti Gaur, Suzanne Petrossian, Anthony Germani, Brian G Till, Jeremy S. Abramson

Blood (2023) 142 (Supplement 1): 2102.

https://doi.org/10.1182/blood-2023-175007

Published: 2023

Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2023) 142 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2023-179868

Published: 2023

Journal Articles

Ilyad: A Phase III Double Blind, Randomized Trial Evaluating Vitamin D (Cholecalciferol) in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy

Jonathan W. Friedberg, Michael T. Brady, Strawderman Myla, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, Barbara L. Averill, Brian K. Link, Paul M. Barr, John P. Leonard, John M. Ashton, Derick R Peterson, Loretta J. Nastoupil

Blood (2023) 142 (Supplement 1): 606.

https://doi.org/10.1182/blood-2023-178088

Published: 2023

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan O. Oluwole, Patrick M. Reagan, David B. Miklos, Frederick L. Locke, Andre Goy, Caron A. Jacobson, Javier L. Munoz, Edouard Forcade, Max S. Topp, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Marie José Kersten, Michael L. Wang

Blood (2023) 142 (Supplement 1): 2120.

https://doi.org/10.1182/blood-2023-174681

Published: 2023

Journal Articles

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Blood (2023) 142 (Supplement 1): 105.

https://doi.org/10.1182/blood-2023-180952

Published: 2023

Journal Articles

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood (2023) 141 (19): 2307–2315.

https://doi.org/10.1182/blood.2022018893

Published: 2023

Includes: Supplemental data

Journal Articles

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Sven de Vos, Patrick M. Reagan, Manish R. Patel, Nakhle S. Saba, Andrew Mortlock, Virginie Cerec, Veerendra Munugalavadla, Melih Acar, Barrett Nuttall, David Jenkins, Rafael White, Megan Callahan, Alessandra Forcina, Mark Roschewski, Ian W. Flinn

Blood (2022) 140 (Supplement 1): 6635–6637.

https://doi.org/10.1182/blood-2022-162447

Published: 2022

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Blood (2022) 140 (Supplement 1): 6623–6626.

https://doi.org/10.1182/blood-2022-157761

Published: 2022

Journal Articles

Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Armin Ghobadi, Javier Munoz, Jason Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph P. McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 1595–1597.

https://doi.org/10.1182/blood-2022-158303

Published: 2022

Journal Articles

Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence

Siba El Hussein, Pingjun Chen, Morteza Salehjahromi, Hong Fang, Wei Wang, Sanam Loghavi, Patrick M. Reagan, Jonathan W. Friedberg, Richard Burack, Andrew G Evans, L. Jeffrey Medeiros, Jia Wu, Joseph D. Khoury

Blood (2022) 140 (Supplement 1): 7836–7837.

https://doi.org/10.1182/blood-2022-166610

Published: 2022

Journal Articles

Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Javier Munoz, Patrick M. Reagan, Andre H. Goy, David B. Miklos, Dan Zheng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Marie José Kersten, Michael Wang

Blood (2022) 140 (Supplement 1): 9320–9322.

https://doi.org/10.1182/blood-2022-158097

Published: 2022

Journal Articles

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Arushi Khurana, Raphael Mwangi, Loretta J. Nastoupil, Patrick M. Reagan, Umar Farooq, Jason T. Romancik, Timothy J. McDonnell, Shaun M Riska, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Thomas E. Witzig, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Grzegorz S. Nowakowski

Blood (2022) 140 (Supplement 1): 2056–2058.

https://doi.org/10.1182/blood-2022-169433

Published: 2022

Journal Articles

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Blood (2022) 139 (9): 1330–1339.

https://doi.org/10.1182/blood.2021013289

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2021) 138 (Supplement 1): 3826.

https://doi.org/10.1182/blood-2021-147488

Published: 2021

Journal Articles

Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Danielle S. Wallace, Andrea M. Baran, Jonathan W. Friedberg, Patrick M. Reagan, Carla Casulo, Mijamin Friend, Alyssa R. Williams, Peter D Dakin, Clive S. Zent, Paul M. Barr

Blood (2021) 138 (Supplement 1): 2640.

https://doi.org/10.1182/blood-2021-145490

Published: 2021

Journal Articles

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Mark Roschewski, Veerendra Munugalavadla, Barrett Nuttall, Kathleen Burke, Melih Acar, Rafael White, Maria Udriste, Shringi Sharma, Brian Dougherty, Ian Flinn, Nakhle S. Saba, Patrick M. Reagan, Sven de Vos, Hendrik-Tobias Arkenau, Graham P. Collins, Andrew Mortlock, Manish R. Patel

Blood (2021) 138 (Supplement 1): 1418.

https://doi.org/10.1182/blood-2021-147567

Published: 2021

Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2.

https://doi.org/10.1182/blood-2021-148039

Published: 2021

Journal Articles

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Blood (2021) 138 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2021-148078

Published: 2021

Journal Articles

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Blood (2021) 138 (12): 1081–1085.

https://doi.org/10.1182/blood.2021010930

Published: 2021

Includes: Supplemental data

NARROW

Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Ilyad: A Phase III Double Blind, Randomized Trial Evaluating Vitamin D (Cholecalciferol) in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence

Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only